Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification. Shimoda Igawa Y, Yoshida T, Makihara R, Torasawa M, et al. Lung Cancer 2024;196:107954.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shimoda Igawa Y, Yoshida T, Makihara R, Torasawa M, et al. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification. Lung Cancer 2024;196:107954.
PMID: 39303401